Bertelsmann Investments acquires stake in AI-powered Israeli healthcare startup QuantHealth
AI-supported start-up company for clinical trial planning
Advertisement
Bertelsmann investments (BI) is investing several million euros in Tel Aviv-based QuantHealth, an AI-powered healthcare startup for planning clinical trials.
More than 90 percent of the drugs that make it to the clinical trial stage never reach the market. The cost of these trials is estimated to be around $50 billion. QuantHealth uses artificial intelligence to simulate hundreds of trials and trial designs to significantly increase a trial’s chance of success and speed up its execution. Based on 350 million patient records, QuantHealth can predict study outcomes with 86 percent accuracy.
Carsten Coesfeld, CEO of Bertelsmann Investments, says: “The QuantHealth team led by co-founder and CEO Orr Inbar recognized very early on what great potential Artificial Intelligence holds for the BioPharma industry. The services QuantHealth provides are unique. I am very pleased that we are contributing to the further development of QuantHealth with our investment.”
Orr Inbar, co-founder and CEO of QuantHealth, stated: “According to a recent Deloitte article, ROI on pharma R&D has steadily declined, reaching 1.2 percent in 2022, the lowest the industry has seen in decades. This decline is happening at a time when the need for efficient drug development has never been greater. We firmly believe that deep AI solutions like ours will dramatically enhance the success of clinical trials, and pave the way towards better and cheaper therapies for patients around the world.”
QuantHealth was able to raise a total of 15 million US dollars in the current round of financing. Bertelsmann Investments and Pitango HealthTech co-led the financing round. Existing investors include Nina Capital, Shoni Top Ventures, Boston Millennia Partners, Atooro Fund, and Renegade Ventures.
Thorsten Wirkes, Senior Vice President at Bertelsmann Investments, commented: “We are very pleased to co-invest in QuantHealth alongside Pitango and to further expand our growth unit Bertelsmann Next with an investment focus on Digital Health. The impressive AI technologies of QuantHealth have proven to save pharmaceutical companies millions, helping them bring drugs to market quicker and get patients the treatments they need.”
Within Bertelsmann Investments, the Bertelsmann Next unit focuses its investments on the fast-growing Digital Health, Mobile Gaming, and HR Tech sectors. Since Next was launched in mid-2022, €70 million has already been invested in the field of digital health. Further investments are to follow.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
First synthesis of open-chain N-stereogenic amines achieved - Study enables enantiomerically pure products for drug development.
The spider with the bee venom - New perspectives for the search for active substances against cell-based diseases - Researchers decode the toxin arsenal of the most poisonous native spider species
Is the immune system younger in the morning? - The internal clock of immune cells
Pancreatic cancer forms "synapses" - Pancreatic tumors use neurotransmitters to drive their own growth: Researchers hope to identify drugs that can block this process
A toxin with a useful twist - Their work opens the door to new applications in lab-on-a-chip technologies, biosensors, and artificial cell prototypes
Gene scissors in camouflage mode help in the search for cancer therapies - Overlooked genes for metastasis formation uncovered
Gene modification enables more functional liver cells from stem cells
Bacteria Borrow Viruses to Spread Their Own Defences - Pseudomonas fluorescens exposed to sterile compost filtrate acquired multiple mobile genetic elements carrying anti-phage defence genes
Opening the door to affordable lab-grown beef, cow cells defy aging - A potential game-changer for creating sustainable, ethical meat without the environmental toll of traditional livestock farming
Synthesizing fine chemicals: Technological Advance in Production of Pharmaceuticals
Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim
